Home > News > QDC announced the appointment of George Dunbar
April 20th, 2004
QDC announced the appointment of George Dunbar
Dunbar’s experience includes more than 25 years as CEO, director, and senior manager with many private and public bioscience companies. Most recently he worked with investors as CEO to sell Targesome, an early-stage targeted drug delivery start-up. Prior to Targesome, Dunbar was CEO of Epic Therapeutics, a controlled release formulation company sold to Baxter Healthcare in 2002.
Nanometrics CFO to Resign for New Job Opportunity August 8th, 2014
California Nanotechnologies Appoints Dr. Enrique Lavernia to the Board August 6th, 2014
ACS Biomaterials Science & Engineering™: Brand-new journal names editor July 29th, 2014
Organometallics welcomes new editor-in-chief: Paul Chirik, Ph.D. July 22nd, 2014